<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4192">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484025</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1005-291</org_study_id>
    <nct_id>NCT04484025</nct_id>
  </id_info>
  <brief_title>SPI-1005 Treatment in Moderate COVID-19 Patients</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center&#xD;
      clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel&#xD;
      SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO Ordinal Scale</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement. Scale is 0-8 where higher score is worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of supplemental oxygen</measure>
    <time_frame>30 days</time_frame>
    <description>Respiratory status assessed by degree of supplemental oxygen (e.g. mask oxygen, mechanical ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Oxygen Saturation (SpO2)</measure>
    <time_frame>30 days</time_frame>
    <description>Peripheral oxygen saturation measured by pulse oximetry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Coronavirus</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>SPI-1005 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 800 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of matching placebo BID for 7 days, with 30-day follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ebselen</intervention_name>
    <description>Glutathione peroxidase mimetic</description>
    <arm_group_label>SPI-1005 400 mg BID</arm_group_label>
    <arm_group_label>SPI-1005 800 mg BID</arm_group_label>
    <other_name>SPI-1005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo containing excipients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥18 years of age&#xD;
&#xD;
          -  Positive nCoV2 PCR test by nasopharyngeal, oral, saliva, or respiratory sample&#xD;
&#xD;
          -  Clinical signs, symptoms, and respiratory status consistent with moderate COVID-19&#xD;
&#xD;
          -  Respiratory status of SpO2 &gt; 94% and respiratory rate &lt; 24 breaths/min without&#xD;
             supplemental oxygen.&#xD;
&#xD;
          -  Score of 3 on the WHO Ordinal Scale (hospitalized, no oxygen treatment)&#xD;
&#xD;
          -  Symptom onset ≤3 days of study enrollment&#xD;
&#xD;
          -  Subject is in-patient at time of randomization to study treatment Subject or legally&#xD;
             authorized representative is willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Participation in another interventional investigational drug or device study&#xD;
             concurrently or within 30 days prior to study consent.&#xD;
&#xD;
          -  Patients with impaired hepatic or renal function.&#xD;
&#xD;
          -  Subject has any other illness or condition that, in the opinion of the investigator,&#xD;
             would prohibit the subject from participating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Treggiari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haifan Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Kil, MD</last_name>
    <phone>2066342559</phone>
    <email>info@soundpharma.com</email>
  </overall_contact>
  <reference>
    <citation>Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.</citation>
    <PMID>32272481</PMID>
  </reference>
  <reference>
    <citation>Menéndez CA, Byléhn F, Perez-Lemus GR, Alvarado W, de Pablo JJ. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease. Sci Adv. 2020 Sep 11;6(37). pii: eabd0345. doi: 10.1126/sciadv.abd0345. Print 2020 Sep.</citation>
    <PMID>32917717</PMID>
  </reference>
  <reference>
    <citation>Weglarz-Tomczak E, Tomczak JM, Talma M, Burda-Grabowska M, Giurg M, Brul S. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci Rep. 2021 Feb 11;11(1):3640. doi: 10.1038/s41598-021-83229-6.</citation>
    <PMID>33574416</PMID>
  </reference>
  <reference>
    <citation>Brown AS, Ackerley DF, Calcott MJ. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor. Molecules. 2020 Oct 13;25(20). pii: E4666. doi: 10.3390/molecules25204666.</citation>
    <PMID>33066278</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ebselen</keyword>
  <keyword>SPI-1005</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Covid</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Mpro</keyword>
  <keyword>main protease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

